A comprehensive literature search was conducted in the Web of Science Core Collection (Science Citation Index Expanded, SCI-E) for publications between January 1, 2014, and December 31, 2024. The search strategy was as follows:

Document types were limited to Article and Review. Only studies published in English were included. A total of 328 articles were obtained.

To ensure the completeness and reliability of the retrieved literature, all publications were retrieved from the Web of Science Core Collection (SCI-E) and the following filtering and deduplication strategies were applied:

Deduplication: Duplicate records were removed using the built-in deduplication feature of Web of Science to avoid repetition of publications, which could interfere with the analysis.

Exclusion Criteria: To ensure the rigor of the analysis, the following types of publications were excluded:

Conference abstracts: Only peer-reviewed full-text journal articles and reviews were included. Non-original research: Case reports, reviews, and non-clinical studies were excluded as they do not contribute new evidence directly relevant to our analysis.

Database Selection: Web of Science Core Collection was selected as the sole data source due to its comprehensive coverage of high-quality journals globally, especially in the medical and life sciences fields. While cross-database searches could increase the breadth of data, this study focused on deep analysis of the Web of Science database. Additionally, Web of Science is considered highly reliable in the fields of medicine and life sciences, encompassing a vast number of influential journals and publications. Time Range (2014–2024): The time range of 2014–2024 was chosen for the following reasons:

Guideline Shifts: After 2014, several major international clinical guidelines (e.g., ASTRO, ESTRO, NCCN) began recommending hypofractionated radiotherapy (HFRT) as a standard treatment for breast cancer, and research from this period directly influenced clinical practice.

Key Studies (e.g., FAST-Forward): Landmark trials such as the FAST-Forward study, published in 2019, provided strong evidence for the use of HFRT. The period from 2014 to 2024 reflects the rapid growth of research in this field, and thus was selected as the time window for this study.

This study systematically searched the literature on hypofractionated radiotherapy for breast cancer from 2014 to 2024. Following the systematic retrieval strategy, data were analyzed using two specialized bibliometric tools: CiteSpace (6.4.R1) and VOSviewer (1.6.20) (8, 9). Using CiteSpace (6.4.R1) software with a 1-year time slice, node types encompassed keywords, institutions, countries, and authors (10–12). The Pathfinder + Pruning sliced networks algorithm was applied for network pruning. Emergent word analysis identified research frontiers, and knowledge maps depicting keyword co-occurrence and literature co-citation were generated (13, 14). Simultaneously, VOSviewer (1.6.20) was employed to visualize research hotspots, developmental trajectories, and collaborative relationships through keyword co-occurrence clustering, systematically outlining the overall development of large-field fractionated radiotherapy for breast cancer over the past decade (12). Figures were generated using CiteSpace (6.4.R1) and VOSviewer (1.6.20) (15, 16).

Based on the Web of Science database, data screening and visualization yielded Figure 1.

Figure 1 illustrates the annual number of publications on hypofractionated radiotherapy (HFRT) for breast cancer from 2014 to 2024 (17). Overall, the publication output demonstrates a fluctuating but upward trajectory, reflecting the progressive maturation of this research field. From 2014 to 2017, the number of publications remained relatively modest, ranging from 18 to 41 articles per year. This period represents an initial exploratory phase, during which hypofractionated radiotherapy had not yet been widely adopted in routine clinical practice, and evidence was mainly derived from early-phase studies and subgroup analyses of randomized trials (18–20). A marked increase was observed in 2018, when annual publications peaked at 43 articles. This surge likely reflects growing academic interest driven by accumulating clinical evidence and the dissemination of landmark trial results, which reinforced the non-inferiority of HFRT compared with conventional fractionation in early-stage breast cancer. Subsequently, publication output declined between 2019 and 2020, reaching a nadir of 14 articles in 2020. This temporary reduction may be attributable to a combination of factors, including the consolidation phase following major efficacy trials, the shift toward long-term follow-up studies requiring extended observation periods, and disruptions to clinical research activity during the COVID-19 pandemic (21). From 2021 onward, the number of publications increased again, with a peak of 42 articles in 2021 and a sustained rise through 2024. This rebound suggests a transition into a more mature research stage, characterized by a shift in focus from efficacy validation toward toxicity profiling, dose optimization, patient-reported outcomes, and the integration of advanced techniques such as image-guided radiotherapy and artificial intelligence–assisted planning. Taken together, the observed publication trend supports a three-phase developmental pattern of HFRT research in breast cancer: an initial exploratory phase (2014–2017), a rapid expansion phase (2018–2021), and a stabilization and refinement phase (2022–2024). This evolution mirrors the gradual translation of HFRT from clinical research into guideline-supported standard practice (22–26).

From 2014 to 2024, a total of 328 authors contributed to research on high-dose fractionated radiotherapy for breast cancer. Each author published between 1 and 8 papers. Due to the large number of authors, only those with at least 4 publications were included in the analysis and visualization, as shown in Figure 2.

Figure 2 presents the distribution of publication output among the most productive authors (≥4 publications) in the field of hypofractionated radiotherapy for breast cancer between 2014 and 2024. Overall, author productivity shows a relatively balanced pattern, with no single author overwhelmingly dominating the research output. The most prolific author contributed eight publications, while a small number of authors published five to six articles. The majority of included authors produced three to four publications during the study period, indicating a moderately distributed authorship structure rather than a highly centralized one. This pattern suggests that research on hypofractionated radiotherapy for breast cancer is driven by multiple active research groups rather than a single dominant team. Such a decentralized authorship structure is consistent with the multicenter and collaborative nature of clinical radiotherapy research, particularly in fields reliant on large randomized trials and long-term follow-up. Furthermore, the relatively narrow range of publication counts among leading authors reflects the maturity of the field, where research contributions are widely shared across institutions and countries, rather than concentrated within a limited number of individual investigators.

Figure 2 also illustrates the publication output of authors who contributed three or more articles to research on hypofractionated radiotherapy for breast cancer between 2014 and 2024. A total of 22 high-productivity authors were identified, reflecting the core group of researchers actively engaged in this field. Among these authors, Pierfrancesco Franco ranked first with eight publications (27),followed by Riccardo Umberto with six publications. Several authors, including Cante Domenico, Dicuonzo Samantha, Poortmans Philip, and Bonfantini Francesca, each contributed five publications, indicating sustained research involvement over the study period. The majority of the remaining authors—such as Choi Francesca, Cosentino Isabelle, De Santis Maria Carmen, Di Cosimo Serena, Fang Hui, Fiorentino Alba, Freedman Gary, Gennaro Massimiliano, Jagsi Reshma, Jing Jing, Jing Hao, Li Yexiong, Marta Gusevskaya, Shin Kyung Hwan, Tang Yu, and Wang Shu-Lian—published four articles each. This relatively narrow range of publication output suggests a balanced authorship structure without excessive concentration of contributions among a small number of individuals. Overall, the author productivity distribution indicates that research on hypofractionated radiotherapy for breast cancer is driven by multiple active investigators and collaborative research groups rather than by a single dominant author. Such a pattern is consistent with the multicenter, multidisciplinary nature of clinical radiotherapy research and reflects the maturity of this research field (28–30).

Only authors with four or more publications were included to improve network clarity and interpretability.

Figure 3 illustrates the author collaboration network in research on hypofractionated radiotherapy for breast cancer from 2014 to 2024. Each node represents an author, while links indicate co-authorship relationships, with larger nodes reflecting higher publication output. The network reveals a moderately connected structure characterized by several prominent collaborative clusters. Among the identified authors, Pierfrancesco Franco occupies a central position within the collaboration network, indicating extensive cooperative relationships with multiple research groups. Authors such as Philip Poortmans, Domenico Cante, Samantha Dicuonzo, and Umberto Ricardi are closely connected to Franco, forming a core European collaboration cluster primarily focused on clinical applications and outcome evaluation of hypofractionated radiotherapy. Additional collaborative subclusters are observed around authors including Marta Gustavo Nader and Kyung Hwan Shin, suggesting regional or institutional research teams that maintain active internal collaboration while also engaging in broader international networks. These clusters highlight the role of multicenter cooperation in advancing hypofractionated radiotherapy research, particularly in studies requiring large patient cohorts and long-term follow-up. Overall, the author collaboration network demonstrates that research in this field is not dominated by isolated investigators but is instead driven by interconnected research groups. This collaborative structure is consistent with the multidisciplinary and multicenter nature of radiotherapy research and supports the robustness and maturity of the research landscape in hypofractionated radiotherapy for breast cancer (31).

Statistics show that 61 countries worldwide participated in research on hypofractionated radiotherapy for breast cancer. Due to the large number of countries, only the top ten countries by publication volume are listed. The success and global adoption of hypofractionated radiotherapy fundamentally exemplify international scientific collaboration. No single nation could have achieved this alone. It was through cross-border collaboration that the efficacy of this therapy was rapidly and robustly validated, transforming global clinical practice. See Figures 4, 5.

Figure 4 presents the international collaboration network of countries involved in research on hypofractionated radiotherapy for breast cancer from 2014 to 2024. Each node represents a country, and the links between nodes indicate international co-authorship relationships. Larger nodes reflect higher publication output, while denser connections indicate stronger collaborative intensity. The network reveals a highly interconnected global research structure, with Italy, the United States, Germany, England, France, Canada, and the People’s Republic of China forming the core contributing countries. Among them, Italy and the United States occupy central positions in the network, demonstrating extensive collaborative links with multiple countries and acting as major hubs of international cooperation. Germany, England, and France also show strong connectivity, particularly within European collaborative networks, reflecting the long-standing tradition of multicenter clinical trials and cross-border research initiatives in radiotherapy. Canada is closely linked with both European countries and the United States, consistent with its active participation in landmark randomized trials in breast cancer radiotherapy. Notably, the People’s Republic of China has emerged as an increasingly connected node in the network, engaging in collaborations with several high-output countries, including the United States and European nations. This pattern indicates the growing international integration of Chinese research groups in hypofractionated radiotherapy studies over the past decade. Overall, the country collaboration network highlights the global and cooperative nature of research in hypofractionated radiotherapy for breast cancer. The strong interconnections among leading countries support the development of high-quality multicenter evidence and facilitate the translation of research findings into international clinical guidelines (32–34).

Figure 5 illustrates the institutional collaboration network in research on hypofractionated radiotherapy for breast cancer from 2014 to 2024. Each node represents an institution, and links between nodes indicate inter-institutional co-authorship. Larger nodes reflect higher publication output, while denser connections indicate stronger collaborative relationships. The network demonstrates a highly interconnected institutional structure, with several prominent academic and clinical centers serving as major hubs. Among them, the University of Milan, UNICANCER, Institut Curie, University of Toronto, University of Cambridge, Harvard University, and the Institute of Cancer Research (UK) occupy central positions, indicating their substantial contributions and extensive collaborative activities. European institutions form a particularly dense collaboration cluster, including the University of Milan, University of Turin, Université PSL, Institut Curie, Royal Marsden NHS Foundation Trust, and University of London. This pattern reflects the strong tradition of multicenter clinical trials and coordinated research frameworks in European radiotherapy research. In parallel, North American institutions such as Harvard University and the University of Toronto are closely integrated into the global collaboration network, frequently partnering with leading European centers. These transcontinental collaborations play a critical role in generating high-quality clinical evidence and facilitating the international dissemination of research findings. Overall, the institutional collaboration network highlights the pivotal role of major academic hospitals and comprehensive cancer centers in advancing hypofractionated radiotherapy research for breast cancer. The extensive inter-institutional connections underscore the multicenter and cooperative nature of this field, which is essential for conducting large-scale clinical trials and achieving long-term follow-up outcomes (35–37).

Using CiteSpace (6.4.R1) and VOSviewer (1.6.20) software, keywords were visualized through co-occurrence analysis, clustering, and highlighting, yielding Figures 6–8.

Figure 6 shows the keyword co-occurrence network generated using VOSviewer, illustrating the relationships among high-frequency keywords in research on hypofractionated radiotherapy for breast cancer. The network is characterized by several densely connected keyword clusters, indicating strong thematic associations across clinical efficacy, toxicity, treatment techniques, and patient-related outcomes. Central keywords such as “breast cancer,” “radiotherapy,” “irradiation,” and “hypofractionation” occupy prominent positions in the network, reflecting their foundational role in this research field. Closely connected terms—including “toxicity,” “local control,” “quality of life,” “partial breast irradiation,” and “conserving surgery”—suggest that current research emphasizes not only oncological outcomes but also treatment safety and patient-centered endpoints. The dense interconnections among keywords related to toxicity (e.g., skin toxicity, fibrosis, cardiac effects) and treatment techniques (e.g., IMRT, boost, target volume) highlight the integrated nature of technical optimization and clinical outcome evaluation in hypofractionated radiotherapy research.

To further clarify the thematic structure of the field, CiteSpace was used to perform keyword clustering analysis (Figure 7). The clustering results demonstrated good structural validity, with a modularity value (Q) of 0.4208 and a weighted mean silhouette score (S) of 0.7467, indicating reliable and well-defined clusters. A total of 11 major keyword clusters were identified. The largest cluster, #0 “accelerated partial breast irradiation,” represents a core research hotspot focused on treatment de-escalation, reduced target volumes, and shortened radiotherapy schedules. Cluster #1 “reconstruction” reflects increasing attention to hypofractionated radiotherapy in patients undergoing breast reconstruction, an area characterized by growing clinical interest but limited high-level evidence. Patient subgroup–specific research is represented by #2 “elderly,” emphasizing treatment tolerance and convenience, while safety-related themes are captured by #3 “acute toxicity” and #4 “fibrosis,” addressing short-term and late adverse effects, respectively. Cluster #5 “dose hypofractionation” highlights ongoing efforts to refine fractionation regimens, whereas #6 “new modalities” reflects technological innovation and emerging treatment approaches. Long-term safety concerns are particularly evident in #7 “cardiac mortality,” underscoring persistent uncertainties regarding cardiotoxicity. Risk stratification and outcome prediction are represented by #8 “risk,” while localized treatment strategies are further explored in #9 “partial breast irradiation.” Finally, #10 “clinical trials” emphasizes the central role of prospective studies in validating hypofractionated radiotherapy strategies.

Figure 8 presents the top 22 keywords with the strongest citation bursts, illustrating the temporal evolution of research focus from 2014 to 2024. Early burst keywords (2014–2017), such as “local control,” “skin toxicity,” “conservative treatment,” “lumpectomy,” and “consensus statement,” reflect the initial emphasis on validating clinical efficacy and short-term safety. During the intermediate period (2018–2020), burst terms including “dose hypofractionation,” “IMRT,” and “American Society” indicate growing attention to dose optimization, advanced radiotherapy techniques, and guideline development. In more recent years (2021–2024), emerging burst keywords such as “partial breast irradiation,” “toxicity,” “female breast,” “phase 3,” and “target volume delineation” highlight a shift toward precision treatment, late toxicity assessment, and high-level evidence generation. Overall, the burst analysis demonstrates a clear transition from early efficacy validation toward refined treatment strategies, patient-specific optimization, and long-term safety evaluation, mirroring the maturation of hypofractionated radiotherapy as a guideline-supported standard of care in breast cancer (38–40).

Visual analysis of highly cited references (≥ citations) using VOSviewer (1.6.20) yielded 224 documents, as shown in Figure 9.

The top three most cited publications were: Whelan TJ et al. (2010) in The New England Journal of Medicine (138 citations), Haviland JS et al. (2013) in The Lancet Oncology (125 citations), and Bentzen SM et al. (2008) in The Lancet (104 citations).

Ranked first is the 2010 study by Whelan TJ et al., published in the New England Journal of Medicine, a landmark achievement in the field of high-dose fractionated radiotherapy for early-stage breast cancer. This multicenter randomized controlled trial enrolled 1,234 patients with early-stage breast cancer (T1-2N0-1) following breast-conserving surgery. Participants were randomized to either the hypofractionated radiotherapy group (42.5 Gy in 16 fractions, completed in 3.2 weeks) or the conventional fractionation group (50Gy/25 fractions, completed in 5 weeks). The primary endpoint was the 5-year local recurrence rate. Results showed no significant statistical difference in 5-year local recurrence rates between groups (6.2% vs 5.9%, P = 0.83), with no apparent differences in distant metastasis rates, overall survival, or disease-free survival. This study provided the first large-scale validation that high-dose fractionated radiotherapy after breast-conserving surgery is non-inferior to conventional fractionation, offering key evidence to support clinical guideline recommendations. Ranked second is the 2013 study by Haviland JS et al. published in The Lancet Oncology, presenting long-term follow-up results from the UK START B trial. This study enrolled 2,236 patients with early-stage breast cancer (including those who underwent breast-conserving or radical surgery) to compare the efficacy of three radiotherapy regimens: conventional fractionation (50 Gy/25 fractions), intermediate fractionation (40 Gy/15 fractions), and hyperfractionated fractionation (36 Gy/12 fractions). After a median follow-up of 10 years, the median local recurrence rate in the intermediate fractionation group (5.2%) showed no significant difference compared to the conventional fractionation group (5.0%) (P = 0.79). Although the rate in the hyperfractionated group (6.8%) was slightly higher, it remained within an acceptable range. Furthermore, no significant statistical differences were observed in long-term toxicities (e.g., fibrosis, breast retraction) among the three groups. This study supports incorporating medium-fractionation regimens (e.g., 40 Gy/15 fractions) into standard treatment options, further solidifying the clinical position of high-fractionation radiotherapy. Ranked third is the 2008 study by Bentzen SM et al. published in The Lancet, which provided crucial theoretical support for high-fractionation radiotherapy from a radiobiological perspective. Based on the Linear-Quadratic (LQ) model, the analysis indicated that breast cancer cells exhibit a relatively low α/β ratio (approximately 3 Gy), making them less sensitive to changes in fractionated doses. Consequently, appropriately reducing the total dose during high-fractionation radiotherapy does not compromise efficacy. This theory clearly elucidates the biological mechanism underpinning the suitability of high-fractionation radiotherapy for breast cancer, providing crucial evidence for designing clinical dose regimens (38, 39, 41–43).

To assess the evolution of clinical evidence supporting hypofractionated radiotherapy, clinical trials were identified through a structured search of the PubMed database. The search strategy combined terms related to breast cancer and hypofractionated radiotherapy. Eligible studies were screened based on predefined criteria, including prospective study design, relevance to breast cancer radiotherapy, and availability of clinical outcome data. Randomized controlled trials and large prospective studies were prioritized. Each included trial was reviewed to extract information on study design, patient population, fractionation regimen, follow-up duration, and key oncological and toxicity outcomes. This process allowed a qualitative assessment of the strength and maturity of clinical evidence in parallel with bibliometric findings.

We identified 6 clinical trials from the PubMed database to evaluate the development of the field of hypofractionated radiotherapy for breast cancer, mainly with the following 6 arguments (44–47):

This study has several limitations that should be acknowledged.

Firstly, although the included clinical trials provide valuable evidence supporting the efficacy and safety of hypofractionated radiotherapy, most landmark randomized controlled trials predominantly enrolled patients with early-stage breast cancer. As a result, the generalizability of these findings to patients with locally advanced disease, postmastectomy settings, or post-reconstruction radiotherapy remains limited.

Secondly, while oncological outcomes such as local control and survival are well documented, long-term follow-up data on cardiac and pulmonary toxicity—particularly beyond 10 years—are relatively scarce. Given the potential for late radiation-related adverse effects, this limitation restricts a comprehensive assessment of long-term safety.

Thirdly, heterogeneity exists among trials with respect to fractionation regimens, boost strategies, target volume definitions, and toxicity assessment methods, which complicates direct comparison across studies. In addition, patient-reported outcomes and cosmetic assessments are inconsistently reported and often underrepresented, especially in younger patient populations.

Finally, the clinical trial evidence summarized in this study was reviewed qualitatively rather than through a formal systematic review or evidence-grading framework. Therefore, the strength of evidence should be interpreted in conjunction with existing guidelines and consensus statements.